Literature DB >> 1389941

Cyclosporin metabolism by human gastrointestinal mucosal microsomes.

I R Webber1, W H Peters, D J Back.   

Abstract

The in vitro metabolism of the immunosuppressant cyclosporin (CsA) by human gastrointestinal mucosal microsomes has been studied. Macroscopically normal intestinal (n = 4) and liver (n = 2) tissue was obtained from kidney transplant donors, and microsomes prepared. Intestinal metabolism was most extensive with duodenal protein (15% conversion to metabolites M1/M17 after 2 h incubation at 37 degrees C; metabolite measurement by h.p.l.c). Western blotting confirmed the presence of P-4503A (enzyme subfamily responsible for CsA metabolism) in duodenum and ileum tissue, but not in colon tissue. The results of this study indicate that the gut wall may play a role in the first-pass metabolism of CsA, and could therefore be a contributory factor to the highly variable oral bioavailability of CsA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389941      PMCID: PMC1381361          DOI: 10.1111/j.1365-2125.1992.tb04098.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

Review 1.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

Review 2.  The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci.

Authors:  D W Nebert; D R Nelson; M Adesnik; M J Coon; R W Estabrook; F J Gonzalez; F P Guengerich; I C Gunsalus; E F Johnson; B Kemper
Journal:  DNA       Date:  1989 Jan-Feb

3.  First-pass metabolism of cyclosporin by the gut.

Authors:  J C Kolars; W M Awni; R M Merion; P B Watkins
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

4.  Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.

Authors:  J F Tjia; D J Back; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

5.  Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

Authors:  T Kronbach; V Fischer; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

6.  Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.

Authors:  J M Tredger; J Grevel; N Naoumov; C M Steward; A A Niven; B Whiting; R Williams
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  The effect of oral metoclopramide on the absorption of cyclosporine.

Authors:  N K Wadhwa; T J Schroeder; E O'Flaherty; A J Pesce; S A Myre; M R First
Journal:  Transplantation       Date:  1987-02       Impact factor: 4.939

8.  The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.

Authors:  T L Schwinghammer; D Przepiorka; R Venkataramanan; C P Wang; G J Burckart; C S Rosenfeld; R K Shadduck
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

9.  Apparent dose-dependent oral absorption of cyclosporin A in rats.

Authors:  C T Ueda; M Lemaire; G Gsell; P Misslin; K Nussbaumer
Journal:  Biopharm Drug Dispos       Date:  1984 Apr-Jun       Impact factor: 1.627

10.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues.

Authors:  I de Waziers; P H Cugnenc; C S Yang; J P Leroux; P H Beaune
Journal:  J Pharmacol Exp Ther       Date:  1990-04       Impact factor: 4.030

View more
  11 in total

Review 1.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

Review 2.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 5.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

6.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 7.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 8.  Cyclosporin pharmacokinetics in the elderly.

Authors:  J M Kovarik; E U Koelle
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 4.271

9.  Development and validation of a HPLC method for the determination of cyclosporine a in new bioadhesive nanoparticles for oral administration.

Authors:  M Pecchio; H Salman; J M Irache; M J Renedo; M C Dios-Viéitez
Journal:  Indian J Pharm Sci       Date:  2014-03       Impact factor: 0.975

10.  Generation of enterocyte-like cells from human induced pluripotent stem cells for drug absorption and metabolism studies in human small intestine.

Authors:  Tatsuya Ozawa; Kazuo Takayama; Ryota Okamoto; Ryosuke Negoro; Fuminori Sakurai; Masashi Tachibana; Kenji Kawabata; Hiroyuki Mizuguchi
Journal:  Sci Rep       Date:  2015-11-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.